Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study
- 26 June 2009
- journal article
- clinical trial
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 23 (12) , 1374-1382
Abstract
To assess patient-reported outcomes (PRO) in patients with moderate-to-severe plaque psoriasis receiving continuous or paused etanercept treatment. In a multicentre European open-label study, one group (n = 352) received continuous therapy: 25 mg subcutaneously (SC) twice weekly (BIW) throughout 54-weeks. The other group (n = 359) received paused therapy: 50 mg SC BIW (<or= 12 weeks) until response was adequate by Physician Global Assessment; after psoriasis returned, retreatment (25 mg BIW) was begun. PRO included the Dermatology Life Quality Index (DLQI), EuroQoL-5D (EQ-5D), Hospital Anxiety and Depression Scale (HADS), and the SF-36 Vitality subscale. At baseline, mean DLQI for patients in the continuous (12.8) and paused group (13.8), indicated significant quality-of-life impairment; mean EQ-5D utility scores were 0.65 and 0.66 for continuous and paused patients, respectively; 30.0% of continuous and 37.0% of paused patients had at least mild symptoms of depression; 40.2% and 48.6%, respectively, had at least mild symptoms of anxiety. At week 54, both groups showed statistically significant (P < 0.05) and meaningful improvement in DLQI and EQ-5D scores; improvements in HADS-D, HADS-A, and SF-36 vitality were also significant. Improvements in DLQI and EQ-5D were significantly greater in the continuous arm than the paused arm, but the differences were not meaningful. Differences between arms in HADS and SF-36 Vitality at week 54 were not significant. At baseline, patients exhibited significant quality-of-life impairment. Both continuous and paused etanercept treatment provided improvements in PRO measures. Either regimen could be considered and care should be individualized.Keywords
This publication has 33 references indexed in Scilit:
- Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trialHealth and Quality of Life Outcomes, 2007
- A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasisJournal of the American Academy of Dermatology, 2007
- Health-Related Quality of Life Measured with EQ-5D in Patients Treated for Depression in Primary CareValue in Health, 2007
- Impact of Stroke on Health-Related Quality of Life in the Noninstitutionalized Population in the United StatesStroke, 2006
- Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trialBritish Journal of Dermatology, 2006
- A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBritish Journal of Dermatology, 2005
- Current severe psoriasis and the Rule of TensBritish Journal of Dermatology, 2005
- Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQIBritish Journal of Dermatology, 1999
- A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjectsPsychological Medicine, 1997
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990